PMID- 34552876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian 
      Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.
PG  - 724620
LID - 10.3389/fonc.2021.724620 [doi]
LID - 724620
AB  - BACKGROUND: PARP inhibitor (PARPi) is an important progress in ovarian cancer 
      treatment. The available evidence suggests that BRCA mutation and homologous 
      recombination deficiency (HRD) are effective biological markers for PARPi. Here 
      we investigated the relationship between adverse events (AEs) and efficacy of 
      PARPi in ovarian cancer patients. METHODS: Seventy-eight patients with ovarian 
      cancer patients underwent Olaparib and Niraparib from July 2018 to July 2020 were 
      analyzed. AEs were assessed by the National Cancer Institute Common Terminology 
      Criteria for Adverse Events (NCI CTCAE) v5.0. Chi-square test or fisher exact 
      tests was performed to observe the association between categorical variables. 
      Logistic regression analysis was conducted to investigate the independent 
      variables for disease control response (DCR). Progression-free survival (PFS) was 
      compared between AEs variables by log-rank test. RESULTS: Patients with AEs in 
      the first one week had a higher DCR compared with those after one week (86.11% 
      versus 60.98%, p=0.013). Patients with serious AEs (SAEs) had a significantly 
      higher DCR (81.40% versus 60.60%, p=0.045). There were associations between 
      anemia and DCR in both occurrence (79.63% versus 56.52%, p=0.037) and grade (100% 
      versus 73.17%, p=0.048). The median PFS of patients with hematological toxicity 
      was longer than that of patients with no-hematological toxicity (30 versus 20 
      weeks, p=0.047). Patients with hematological toxicity within four weeks had 
      prolonged median PFS than those with hematological toxicity after four weeks (40 
      versus 22 weeks, p=0.003). CONCLUSIONS: The early presence of AEs and SAEs in 
      hematological toxicity of PARPi were related to the antitumor efficacy, which 
      might be a valid and easily measurable clinical marker in ovarian cancer 
      patients.
CI  - Copyright (c) 2021 Ni, Cheng, Zhou, Zhao, Xu, Guo, Gu, Chen and Chen.
FAU - Ni, Jing
AU  - Ni J
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Cheng, Xianzhong
AU  - Cheng X
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Zhou, Rui
AU  - Zhou R
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Zhao, Qian
AU  - Zhao Q
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Xu, Xia
AU  - Xu X
AD  - Department of Chemotherapy, The Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Guo, Wenwen
AU  - Guo W
AD  - Department of Pathology, The Second Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Gu, Hongyuan
AU  - Gu H
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Chen, Chen
AU  - Chen C
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Chen, Xiaoxiang
AU  - Chen X
AD  - Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20210906
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8450569
OTO - NOTNLM
OT  - PARP inhibitor
OT  - adverse events
OT  - clinical marker
OT  - efficacy
OT  - ovarian cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/24 06:00
MHDA- 2021/09/24 06:01
PMCR- 2021/01/01
CRDT- 2021/09/23 06:53
PHST- 2021/06/13 00:00 [received]
PHST- 2021/08/19 00:00 [accepted]
PHST- 2021/09/23 06:53 [entrez]
PHST- 2021/09/24 06:00 [pubmed]
PHST- 2021/09/24 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.724620 [doi]
PST - epublish
SO  - Front Oncol. 2021 Sep 6;11:724620. doi: 10.3389/fonc.2021.724620. eCollection 
      2021.